Finance
US announces zero tariff pharmaceutical deal with Britain
Published by Global Banking and Finance Review
Posted on December 1, 2025
2 min readLast updated: January 20, 2026
Global Banking and Finance Review
Company
Published by Global Banking and Finance Review
Posted on December 1, 2025
2 min readLast updated: January 20, 2026
The US and UK have announced a zero tariff deal on pharmaceuticals, increasing NHS medicine spending and exempting UK-made drugs from tariffs.
By Andrea Shalal, Maggie Fick and Alistair Smout
WASHINGTON/LONDON, Dec 1 (Reuters) - The United States announced a deal with Britain for zero tariffson pharmaceutical products and medical technology on Monday which will lead to Britain spending more on medicines.
The deal included an increase in the percentage of the state-run National Health Service (NHS) budget that is spent on medicines.
"The United States and the United Kingdom announce this negotiated outcome pricing for innovative pharmaceuticals, which will help drive investment and innovation in both countries," United States Trade Representative Jamieson Greer said in a statement.
The office of the USTR statement said that Britain would increase the net price it pays for new medicines by 25% under the deal. In exchange, UK-made medicines, drug ingredients and medical technology would be exempted from so-called Section 232 sectoral tariffs.
Two sources familiar with the deal said it involved a major change in the value appraisal framework at NICE, a UK government body that determines whether new drugs are cost-effective for the NHS, the sources said.
NICE's "quality-adjusted life year" measures the cost of a treatment for each healthy year it enables for a patient, with the upper threshold being 30,000 pounds ($39,789) per year.
U.S. President Donald Trump has pressed Britain and the rest of Europe to pay more for American medicines, part of his push for U.S. medicine costs to be brought more in line with those paid in other wealthy nations.
The pharmacutical industry has criticised a tough operating environment in Britain and some major firms have cancelled or paused investment in Britain, including AstraZeneca, the largest firm on the London Stock Exchange by market value.
One point of contention between the sector and the government has been the operation of a voluntary pricing scheme which sees firms put a proportion of sales to the NHS back in to the health service.
The office of the USTR said Britain had committed that the rebate rate would decrease to 15% in 2026.
($1 = 0.7540 pounds)
(Reporting by Maggie Fick and Alistair Smout in London, Andrea Shalal in WashingtonEditing by Bernadette Baum, Frances Kerry and Louise Heavens)
The main topic is the zero tariff pharmaceutical deal between the US and UK, which impacts medicine pricing and trade.
The NHS budget for medicines will increase by 25% under the new deal.
UK-made medicines will be exempt from Section 232 tariffs as part of the deal.
Explore more articles in the Finance category
